EF Hutton analyst Michael King initiated coverage of Sonnet BioTherapeutics with a Buy rating and $6.70 price target. Sonnet is a small-cap biotech company utilizing sophisticated protein engineering to maximize the benefits of timeless cytokines, King tells investors in a research note. The analyst says the company "leverages the many protein players mixing it up in the tumor microenvironment."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly